Novo-Nordisk

NVO-N

NYSE:NVO

72.20
1.17 (1.65%)
Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries.
More at Wikipedia

Analysis and Opinions about NVO-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
July 26, 2006
His favourite pharmaceutical. 1.5% dividend and dividend growth has been 20% over the last 5 years. Largest supplier of insulin in the world. Rate of diabetes continues to rise. Cheap at this price.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
July 26, 2006
His favourite pharmaceutical. 1.5% dividend and dividend growth has been 20% over the last 5 years. Largest supplier of insulin in the world. Rate of diabetes continues to rise. Cheap at this price.
BUY
BUY
February 23, 2006
Past Top pick. Insulin demain is growing over the next 20 years. It's still a long term investment.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
February 23, 2006
Past Top pick. Insulin demain is growing over the next 20 years. It's still a long term investment.
TOP PICK
TOP PICK
November 3, 2005
Manufactures insulin. Human insulin is in huge demand and they control the market. Good earnings last quarter. Good price.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 3, 2005
Manufactures insulin. Human insulin is in huge demand and they control the market. Good earnings last quarter. Good price.
TOP PICK
TOP PICK
August 3, 2005
The growth in cases of diabetes in the next 20 years is expected to double from 3 to 6 hundred million globally. The stock had fallen from $58 to the low $50's because their drug was going to be delayed. Stock is now getting interesting.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 3, 2005
The growth in cases of diabetes in the next 20 years is expected to double from 3 to 6 hundred million globally. The stock had fallen from $58 to the low $50's because their drug was going to be delayed. Stock is now getting interesting.
PAST TOP PICK
PAST TOP PICK
June 8, 2004
(A top pick Dec 1/03. Up 30%.) The cases of diabetics is expected to double.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
June 8, 2004
(A top pick Dec 1/03. Up 30%.) The cases of diabetics is expected to double.
TOP PICK
TOP PICK
December 11, 2003
In pharmaceuticals, they devote most money per revenue into R&D. Demographically, feels that China and India will be strong future markets.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
December 11, 2003
In pharmaceuticals, they devote most money per revenue into R&D. Demographically, feels that China and India will be strong future markets.
TOP PICK
TOP PICK
August 22, 2001
Takeover target. Diabetes is growing. Expects 10/15% growth over time.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 22, 2001
Takeover target. Diabetes is growing. Expects 10/15% growth over time.
BUY
BUY
August 7, 2001
Great company. Will do well.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
August 7, 2001
Great company. Will do well.
TOP PICK
TOP PICK
June 22, 2001
Trading at FMV. 33% growth in diabetes.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
June 22, 2001
Trading at FMV. 33% growth in diabetes.
TOP PICK
TOP PICK
June 4, 2001
Just split. Growing 40% in sales. Growth is in the 30/40% range.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
June 4, 2001
Just split. Growing 40% in sales. Growth is in the 30/40% range.
BUY
BUY
March 27, 2001
Bullet proof portfolio-mid caps (35%)
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
March 27, 2001
Bullet proof portfolio-mid caps (35%)
TOP PICK
TOP PICK
February 28, 2001
Good earnings. Growing at 50% a year.
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
February 28, 2001
Good earnings. Growing at 50% a year.
BUY
BUY
November 6, 2000
Held their own in market drop. Good price now
Show full opinionHide full opinion
Novo-Nordisk (NVO-N)
November 6, 2000
Held their own in market drop. Good price now
Showing 76 to 88 of 88 entries